Rakuten Medical, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, today announced that enrollment is underway in its global, pivotal Phase 3 clinical trial evaluating lead product candidate ASP-1929 in patients with recurrent local regional head and neck squamous cell carcinomas (HNSCC). Rakuten Medical expects to enroll 275 patients at 75 sites in the U.S., Europe and Asia…click here to continue reading